$ANNA
AleAnna, Inc.

2023 Q4 Form 10-K Financial Statement

#000119312524083443 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses -$196.2K $3.085M
YoY Change -143.37% 112.38%
Operating Profit -$3.085M
YoY Change 112.38%
Interest Expense $289.4K $6.502M
YoY Change -82.01% 155.73%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0%
Pretax Income $485.6K $3.417M
YoY Change -58.01% 222.38%
Income Tax
% Of Pretax Income
Net Earnings $485.6K $3.417M
YoY Change -58.01% 222.38%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.04 $0.22
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.4K $148.4K
YoY Change -67.88% -67.88%
Cash & Equivalents $148.3K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Inventory
Prepaid Expenses $0.00
Receivables
Other Receivables
Total Short-Term Assets $148.3K $148.4K
YoY Change -84.8% -84.8%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $24.38M $24.38M
YoY Change -89.39% -89.39%
Other Assets
YoY Change
Total Long-Term Assets $24.38M $24.38M
YoY Change -89.39% -89.39%
TOTAL ASSETS
Total Short-Term Assets $148.3K $148.4K
Total Long-Term Assets $24.38M $24.38M
Total Assets $24.52M $24.52M
YoY Change -89.37% -89.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.016M $2.016M
YoY Change 3817.62% 3817.84%
Accrued Expenses $185.3K $552.3K
YoY Change -63.25% -35.72%
Deferred Revenue
YoY Change
Short-Term Debt $600.0K $600.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.170M $3.170M
YoY Change 247.29% 247.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.170M $3.170M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $3.170M $3.170M
YoY Change -63.92% -63.92%
SHAREHOLDERS EQUITY
Retained Earnings -$2.922M
YoY Change -62.11%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.922M $21.35M
YoY Change
Total Liabilities & Shareholders Equity $24.52M $24.52M
YoY Change -89.37% -89.37%

Cashflow Statement

Concept 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $485.6K $3.417M
YoY Change -58.01% 222.38%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$121.4K -$913.6K
YoY Change 75.58% 120.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $10.00 $211.9M
YoY Change -939.28%
Cash From Investing Activities $10.00 $211.9M
YoY Change -939.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $211.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K -211.3M
YoY Change -936.9%
NET CHANGE
Cash From Operating Activities -121.4K -913.6K
Cash From Investing Activities 10.00 211.9M
Cash From Financing Activities 200.0K -211.3M
Net Change In Cash 78.57K -313.6K
YoY Change -213.61% -24.24%
FREE CASH FLOW
Cash From Operating Activities -$121.4K -$913.6K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001845123
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity Registrant Name
EntityRegistrantName
Swiftmerge Acquisition Corp.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2023 dei Entity File Number
EntityFileNumber
001-41164
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1582153
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
4318 Forman Ave
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Toluca Lake
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91602
CY2023 dei City Area Code
CityAreaCode
424
CY2023 dei Local Phone Number
LocalPhoneNumber
431-0030
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
23210580
CY2023Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Current Related Party Type Extensible Enumeration
OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023 ivcp Period To Redeem Public Shares If Business Combination Is Not Completed Within Initial Combination Period
PeriodToRedeemPublicSharesIfBusinessCombinationIsNotCompletedWithinInitialCombinationPeriod
P10D
CY2023Q4 us-gaap Notes Payable Current Related Party Type Extensible Enumeration
NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Notes Payable Current Related Party Type Extensible Enumeration
NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023 dei Auditor Location
AuditorLocation
Hartford, CT
CY2023Q4 us-gaap Cash
Cash
148349
CY2022Q4 us-gaap Cash
Cash
461914
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
514200
CY2023Q4 us-gaap Assets Current
AssetsCurrent
148349
CY2022Q4 us-gaap Assets Current
AssetsCurrent
976114
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
24376178
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
229792494
CY2023Q4 us-gaap Assets
Assets
24524527
CY2022Q4 us-gaap Assets
Assets
230768608
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2015734
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
51453
CY2023Q4 ivcp Accrued Offering Costs Current
AccruedOfferingCostsCurrent
-311430
CY2022Q4 ivcp Accrued Offering Costs Current
AccruedOfferingCostsCurrent
-311430
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2284
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2284
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
185310
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
504181
CY2023Q4 ivcp Accrued Expenses Related Party
AccruedExpensesRelatedParty
55516
CY2022Q4 ivcp Accrued Expenses Related Party
AccruedExpensesRelatedParty
43516
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
600000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2023Q4 us-gaap Liabilities
Liabilities
3170274
CY2022Q4 us-gaap Liabilities
Liabilities
912864
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
2246910
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
2246910
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
22500000
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
22500000
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.8
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.21
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
24276178
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
229692494
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
0
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2922487
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
162688
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2921925
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
163250
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24524527
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
230768608
CY2023 ivcp Formation And Operating Costs
FormationAndOperatingCosts
3085175
CY2022 ivcp Formation And Operating Costs
FormationAndOperatingCosts
1452694
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-3085175
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1452694
CY2023 ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
0
CY2022 ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
30000
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
6501789
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2542494
CY2023 ivcp Gain On Waiver Of Deferred Under Writing Fee Payable
GainOnWaiverOfDeferredUnderWritingFeePayable
0
CY2022 ivcp Gain On Waiver Of Deferred Under Writing Fee Payable
GainOnWaiverOfDeferredUnderWritingFeePayable
442750
CY2023 us-gaap Net Income Loss
NetIncomeLoss
3416614
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1502550
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5484056
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1181250
CY2022 ivcp Proceeds From Sale Of Private Placement Warrants Net Of Offering Costs
ProceedsFromSaleOfPrivatePlacementWarrantsNetOfOfferingCosts
780000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2442494
CY2022 ivcp Adjustment To Additional Paid In Capital Accretion Of Class A Ordinary Shares From Issuance Of Overallotment Warrants
AdjustmentToAdditionalPaidInCapitalAccretionOfClassAOrdinarySharesFromIssuanceOfOverallotmentWarrants
2806250
CY2022 ivcp Forgiveness Of Deferred Underwriting Fee Payable
ForgivenessOfDeferredUnderwritingFeePayable
7432250
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1502550
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
163250
CY2023 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
6501789
CY2023 us-gaap Net Income Loss
NetIncomeLoss
3416614
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2921925
CY2023 us-gaap Net Income Loss
NetIncomeLoss
3416614
CY2022 us-gaap Net Income Loss
NetIncomeLoss
1502550
CY2023 ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
0
CY2022 ivcp Loss On Sale Of Private Placement Warrants
LossOnSaleOfPrivatePlacementWarrants
30000
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
6501789
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
2542494
CY2023 ivcp Gain On Waiver Of Deferred Under Writing Fee Payable
GainOnWaiverOfDeferredUnderWritingFeePayable
0
CY2022 ivcp Gain On Waiver Of Deferred Under Writing Fee Payable
GainOnWaiverOfDeferredUnderWritingFeePayable
442750
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-514200
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-560833
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1964281
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
18394
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-318871
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
429305
CY2023 ivcp Accrued Offering Costs
AccruedOfferingCosts
0
CY2022 ivcp Accrued Offering Costs
AccruedOfferingCosts
-8755
CY2023 ivcp Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
12000
CY2022 ivcp Increase Decrease In Accrued Liabilities Related Party
IncreaseDecreaseInAccruedLiabilitiesRelatedParty
39000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-913565
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-413917
CY2023 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
CY2022 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
25250000
CY2023 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
211918105
CY2022 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
211918105
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25250000
CY2023 ivcp Proceeds From Issuance Initial Public Offering Net Of Underwriting Discount
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingDiscount
0
CY2022 ivcp Proceeds From Issuance Initial Public Offering Net Of Underwriting Discount
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingDiscount
24500000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
750000
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
211918105
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
600000
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-211318105
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25250000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-313565
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-413917
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461914
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
875831
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148349
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
461914
CY2023 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
337
CY2022 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2023 ivcp Total Accretion Of Class A Ordinary Shares Subject To Redemption Value
TotalAccretionOfClassAOrdinarySharesSubjectToRedemptionValue
6501789
CY2022 ivcp Total Accretion Of Class A Ordinary Shares Subject To Redemption Value
TotalAccretionOfClassAOrdinarySharesSubjectToRedemptionValue
5248744
CY2023 ivcp Deferred Underwriting Fee Incurred But Not Yet Paid
DeferredUnderwritingFeeIncurredButNotYetPaid
0
CY2022 ivcp Deferred Underwriting Fee Incurred But Not Yet Paid
DeferredUnderwritingFeeIncurredButNotYetPaid
-6557250
CY2023 ivcp Forfeiture Of Ordinary Shares By Sponsor
ForfeitureOfOrdinarySharesBySponsor
0
CY2022 ivcp Forfeiture Of Ordinary Shares By Sponsor
ForfeitureOfOrdinarySharesBySponsor
13
CY2021Q4 ivcp Term Of Restricted Investments
TermOfRestrictedInvestments
P185D
CY2023Q4 ivcp Number Of Operating Businesses Included In Initial Business Combination
NumberOfOperatingBusinessesIncludedInInitialBusinessCombination
1
CY2023Q4 ivcp Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.1
CY2023Q4 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
5000001
CY2023Q4 ivcp Percentage Of Public Shares That Can Be Redeemed Without Prior Consent
PercentageOfPublicSharesThatCanBeRedeemedWithoutPriorConsent
0.15
CY2023Q4 ivcp Percentage Of Public Shares That Would Not Be Redeemed If Business Combination Is Not Completed With In Initial Combination Period
PercentageOfPublicSharesThatWouldNotBeRedeemedIfBusinessCombinationIsNotCompletedWithInInitialCombinationPeriod
1
CY2023 ivcp Period To Complete Business Combination From Closing Of Initial Public Offering
PeriodToCompleteBusinessCombinationFromClosingOfInitialPublicOffering
P18D
CY2023 ivcp Period To Complete Business Combination From Closing Of Initial Public Offering
PeriodToCompleteBusinessCombinationFromClosingOfInitialPublicOffering
P18D
CY2023Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2021Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.1
CY2023Q4 ivcp Cash Deposited In Trust Account Per Unit
CashDepositedInTrustAccountPerUnit
10.1
CY2023Q4 us-gaap Cash
Cash
148349
CY2023Q4 ivcp Working Capital Surplus
WorkingCapitalSurplus
3021925
CY2022Q3 ivcp Percentage Of Excise Tax On Repurchases Of Stock
PercentageOfExciseTaxOnRepurchasesOfStock
0.01
CY2022Q3 ivcp Percentage Of Amount Of Excise Tax Is Equal To Amount Of Fair Market Value Of The Shares Repurchased
PercentageOfAmountOfExciseTaxIsEqualToAmountOfFairMarketValueOfTheSharesRepurchased
0.01
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div>
CY2023Q4 us-gaap Cash
Cash
148349
CY2022Q4 us-gaap Cash
Cash
461914
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20600000
CY2023Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
24376178
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
229792494
CY2023Q4 us-gaap Liquidation Basis Of Accounting Accrued Costs To Dispose Of Assets And Liabilities
LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
100000
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
1250000
CY2022 ivcp Temporary Equity Stock Issuance Cost
TemporaryEquityStockIssuanceCost
-1556250
CY2022 ivcp Proceeds From Overallotment Warrants
ProceedsFromOverallotmentWarrants
750000
CY2022 ivcp Proceeds From Issuance Initial Public Offering Net Of Underwriting Discount
ProceedsFromIssuanceInitialPublicOfferingNetOfUnderwritingDiscount
24500000
CY2022 ivcp Initial Accretion From Overallotment Warrants
InitialAccretionFromOverallotmentWarrants
2806250
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2442494
CY2023 ivcp Temporary Equity Redemptions
TemporaryEquityRedemptions
-211918105
CY2023 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
6501789
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</div>
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3000000
CY2021Q4 ivcp Cash Deposited In To Operating Bank Account
CashDepositedInToOperatingBankAccount
2600000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
one-for-one

Files In Submission

Name View Source Status
0001193125-24-083443-index-headers.html Edgar Link pending
0001193125-24-083443-index.html Edgar Link pending
0001193125-24-083443.txt Edgar Link pending
0001193125-24-083443-xbrl.zip Edgar Link pending
d767749d10k.htm Edgar Link pending
d767749dex311.htm Edgar Link pending
d767749dex312.htm Edgar Link pending
d767749dex321.htm Edgar Link pending
d767749dex322.htm Edgar Link pending
d767749dex45.htm Edgar Link pending
d767749dex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ivcp-20231231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ivcp-20231231_cal.xml Edgar Link unprocessable
ivcp-20231231_def.xml Edgar Link unprocessable
ivcp-20231231_lab.xml Edgar Link unprocessable
ivcp-20231231_pre.xml Edgar Link unprocessable
d767749d10k_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending